Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ImmunAg is a private India-based health and wellness company commercializing a botanical cannabinoid ingredient derived from its patented Kriya Hops plant rather than hemp or cannabis. The company markets ImmunAg, described as a Humulus CBD oil containing cannabidiol together with beta-caryophyllene and alpha-humulene, and positions the product as a legal non-cannabis cannabinoid ingredient for wellness use in markets where cannabis-derived products may be restricted. Its business appears centered on cultivation, extraction, ingredient supply, and direct-to-consumer sales rather than a conventional prescription drug pipeline. Publicly available information suggests ImmunAg operates as ImmunAg LLP from Goa, India and emphasizes food-ingredient certification, organic sourcing, and processing in an FDA-approved food facility.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ImmunAg.